{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:33:44Z","timestamp":1791160424639,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001230","name":"Macquarie University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cancer treatment remains a significant and escalating healthcare expense worldwide. Although annual reports on total cancer care costs are available, the potential impact of evolving treatment guidelines and the introduction of new drugs on future budgeting remains largely uncertain. The aim of this study was to examine the trends in the use of Pharmaceutical Benefits Scheme (PBS)-subsidised cancer drugs in Australia over the past decade.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PBS codes for all PBS-subsidised cancer drugs that were listed in government-endorsed treatment protocols were obtained and used to retrieve usage data. Their patterns of use, represented by the number of prescriptions (services) processed by Services Australia, were analysed for the period between 2012 and 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall prescribing of cancer drugs is outpacing Australia\u2019s population growth, primarily due to an ageing population and the accelerated rise in cancer diagnoses observed over the past decade. From 846 eviQ protocols, 141 cancer drugs were available on the PBS, of which kinase inhibitor (39 drugs) and monoclonal antibody drugs (24 drugs) had the highest increase in use during the study period; 16% and 23% respectively. Of the 8 drug classes, hormonal agents (20 drugs) were the most prescribed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The utilisation of PBS-listed cancer drugs is increasing faster than population growth, especially for high-cost monoclonal antibody and kinase inhibitor drugs, indicating continued pressure on government spending.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05889-x","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:03:15Z","timestamp":1722452595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An analysis of the trends in the usage of Pharmaceutical Benefits Scheme-subsidised cancer drugs in Australia from 2012 to 2022"],"prefix":"10.1007","volume":"150","author":[{"given":"Jasmine","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Panagiotelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nial J.","family":"Wheate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"1","key":"5889_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009586","volume":"6","author":"H Andrew","year":"2016","unstructured":"Andrew H, Dzintars G, Joseph F, Jonathan M, Isabelle E, Manuel M et al (2016) Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open 6(1):e009586. https:\/\/doi.org\/10.1136\/bmjopen-2015-009586","journal-title":"BMJ Open"},{"key":"5889_CR2","unstructured":"Australian Bureau of Statistics (2023) Population statistics. Australian Bureau of Statistics. [Internet]. Canberra: Australian Bureau of Statistics. https:\/\/www.abs.gov.au\/statistics\/people\/population. Cited 10 Oct 2023"},{"key":"5889_CR3","unstructured":"Australian Institute of Health and Welfare (2021) Health system expenditure on cancer and other neoplasms in Australia, 2015\u201316. Canberra: Australian Institute of Health and Welfare"},{"key":"5889_CR4","unstructured":"Australian Institute of Health and Welfare (2023) Cancer data in Australia [Internet]. Canberra: Australian Institute of Health and Welfare. https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/cancer-incidence-by-age-visualisation. Cited 16 Oct 2023"},{"key":"5889_CR5","unstructured":"Cancer Australia (2022) Targeted therapy [Internet]. Canberra: Australian Government Department of Health; [updated Jan 15, 2022]. https:\/\/www.canceraustralia.gov.au\/impacted-cancer\/treatment\/targeted-therapy. Cited 16 Oct 2023"},{"issue":"7","key":"5889_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 20(7):551\u2013569. https:\/\/doi.org\/10.1038\/s41573-021-00195-4","journal-title":"Nat Rev Drug Discov"},{"key":"5889_CR7","unstructured":"eviQ Cancer Treatments Online (2024) Sydney: Cancer Institute NSW; c2023 www.eviq.org.au. Cited 6 Oct 2023"},{"issue":"5","key":"5889_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson FM, Gray NS (2018) Kinase inhibitors: the road ahead. Nat Rev Drug Discov 17(5):353\u2013377. https:\/\/doi.org\/10.1038\/nrd.2018.21","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"5889_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201552","volume":"13","author":"DE Goldsbury","year":"2018","unstructured":"Goldsbury DE, Yap S, Weber MF, Veerman L, Rankin N, Banks E et al (2018) Health services costs for cancer care in Australia: estimates from the 45 and Up Study. PLoS ONE 13(7):e0201552. https:\/\/doi.org\/10.1371\/journal.pone.0201552","journal-title":"PLoS ONE"},{"issue":"1","key":"5889_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","volume":"37","author":"AL Grilo","year":"2019","unstructured":"Grilo AL, Mantalaris A (2019) The increasingly human and profitable monoclonal antibody market. Trends Biotechnol 37(1):9\u201316. https:\/\/doi.org\/10.1016\/j.tibtech.2018.05.014","journal-title":"Trends Biotechnol"},{"issue":"43","key":"5889_CR11","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"MA Hadley Wickham","year":"2022","unstructured":"Hadley Wickham MA, Bryan J, Chang W, McGowan LD, Fran\u00e7ois R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, M\u00fcller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H (2022) Welcome to the tidyverse. J Open Sour Softw. 4(43):1686","journal-title":"J Open Sour Softw."},{"issue":"2","key":"5889_CR12","first-page":"109","volume":"24","author":"I Hernandez","year":"2018","unstructured":"Hernandez I, Bott SW, Patel AS, Collin WG, Hospodar AR, Sampathkumar S, Shrank WH (2018) Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care 24(2):109\u2013112","journal-title":"Am J Manag Care"},{"issue":"8","key":"5889_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.12998\/wjcc.v6.i8.161","volume":"6","author":"F Kaida-Yip","year":"2018","unstructured":"Kaida-Yip F, Deshpande K, Saran T, Vyas D (2018) Biosimilars: review of current applications, obstacles, and their future in medicine. World J Clin Cases. 6(8):161\u2013166. https:\/\/doi.org\/10.12998\/wjcc.v6.i8.161","journal-title":"World J Clin Cases."},{"issue":"4","key":"5889_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1743-7563.2011.01431.x","volume":"7","author":"JM Langton","year":"2011","unstructured":"Langton JM, Pearson SA (2011) eviQ cancer treatments online: how does the web-based protocol system fare in a comprehensive quality assessment? Asia Pac J Clin Oncol 7(4):357\u2013363. https:\/\/doi.org\/10.1111\/j.1743-7563.2011.01431.x","journal-title":"Asia Pac J Clin Oncol"},{"key":"5889_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE (2018) Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol 834:188\u2013196. https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.034","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"5889_CR16","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1002\/bit.27774","volume":"118","author":"H Mahal","year":"2021","unstructured":"Mahal H, Branton H, Farid SS (2021) End-to-end continuous bioprocessing: impact on facility design, cost of goods, and cost of development for monoclonal antibodies. Biotechnol Bioeng 118(9):3468\u20133485. https:\/\/doi.org\/10.1002\/bit.27774","journal-title":"Biotechnol Bioeng"},{"key":"5889_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8","author":"L Mellish","year":"2015","unstructured":"Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ et al (2015) The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes. https:\/\/doi.org\/10.1186\/s13104-015-1616-8","journal-title":"BMC Res Notes"},{"issue":"10","key":"5889_CR18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/nejmoa1413204","volume":"372","author":"HCF Moore","year":"2015","unstructured":"Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923\u2013932. https:\/\/doi.org\/10.1056\/nejmoa1413204","journal-title":"N Engl J Med"},{"key":"5889_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E P\u00e9rez-Herrero","year":"2015","unstructured":"P\u00e9rez-Herrero E, Fern\u00e1ndez-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52\u201379. https:\/\/doi.org\/10.1016\/j.ejpb.2015.03.018","journal-title":"Eur J Pharm Biopharm"},{"key":"5889_CR20","first-page":"81","volume-title":"Monoclonal antibodies: past, present and future","author":"J Posner","year":"2019","unstructured":"Posner J, Barrington P, Brier T, Datta-Mannan A (2019) Monoclonal antibodies: past, present and future. Springer International Publishing, pp 81\u2013141"},{"key":"5889_CR21","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-P1-08-18","author":"X Qin","year":"2019","unstructured":"Qin X, Huckfeldt P, Virnig B (2019) Abstract P1\u201308-18: initiating adjuvant endocrine therapy: choice of drugs and changes in the patent status of aromatase inhibitors. AACR. https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-P1-08-18","journal-title":"AACR."},{"key":"5889_CR22","unstructured":"R Core Team (2023) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"key":"5889_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011346.pub2","author":"S Sarwar","year":"2016","unstructured":"Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M et al (2016) Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd011346.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5889_CR24","unstructured":"Services Australia (2022) PBS expenditure and prescriptions report 1 July 2021 to 30 June 2022. Canberra: Australian Government Department of Health"},{"key":"5889_CR25","unstructured":"Services Australia (2023) About the PBS. Pharmaceutical benefits scheme. [Internet]. Canberra: Australian Government Department of Health. https:\/\/www.pbs.gov.au\/info\/about-the-pbs. Cited 7 Oct 2023"},{"key":"5889_CR26","unstructured":"Services Australia (2024a) PBS: co-payment reduction Australia. [Internet]. Canberra: Australian Government Department of Health. https:\/\/www.pbs.gov.au\/info\/healthpro\/co-payment-reduction. Cited 13 May 2024"},{"key":"5889_CR27","unstructured":"Services Australia (2024b) Pharmaceutical Benefits Schedule Item Reports. [Internet]. Canberra: Australian Government Department of Health. http:\/\/medicarestatistics.humanservices.gov.au\/statistics\/pbs_item.jsp. Cited 17 May 2024"},{"issue":"1","key":"5889_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/14737167.2014.868310","volume":"14","author":"C Shen","year":"2014","unstructured":"Shen C, Chien C-R, Geynisman DM, Smieliauskas F, Shih Y-CT (2014) A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res 14(1):45\u201369. https:\/\/doi.org\/10.1586\/14737167.2014.868310","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"5889_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14067","author":"JV Shingleton","year":"2024","unstructured":"Shingleton JV, Stapleton BW, Kelly AP, Ward RL, Lean CL, Rushton SA, O\u2019Brien TA (2024) eviQ cancer treatments online: providing evidence-based information to improve cancer patient outcomes. Asia Pac J Clin Oncol. https:\/\/doi.org\/10.1111\/ajco.14067","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"5889_CR30","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1007\/s00432-023-04575-8","volume":"149","author":"LR Soldi","year":"2023","unstructured":"Soldi LR, Silva VLC, Rabelo DH, Uehara IA, Silva MJB (2023) Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. J Cancer Res Clin Oncol 149(9):6661\u20136673. https:\/\/doi.org\/10.1007\/s00432-023-04575-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"5889_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05715-4","author":"F Springer","year":"2024","unstructured":"Springer F, Mehnert-Theuerkauf A, Gebhardt C, Stolzenburg J-U, Briest S (2024) Unmet supportive care needs among cancer patients: exploring cancer entity-specific needs and associated factors. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-024-05715-4","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"5889_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s1470-2045(11)70141-3","volume":"12","author":"R Sullivan","year":"2011","unstructured":"Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E et al (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12(10):933\u2013980. https:\/\/doi.org\/10.1016\/s1470-2045(11)70141-3","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05889-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:03:28Z","timestamp":1727377408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["5889"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05889-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval by a Human Research Ethics Committee was not required as the analysis utilised only publicly available aggregated data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"375"}}